In such a case, these opposing signals might not lead to any evident Notch activation in CLL cells, so that, anti-Jag1 antibodies, by blocking both types of Notch-Jag1 interactions, might not have any evident effect. This evidence concerns the gene JAG1 and B-cell chronic lymphocytic leukemia.